Outcomes of transition from premixed and intensive insulin therapies to insulin aspart/degludec co-formulation in type 2 diabetes mellitus: a real-world experience

---

Ozcelik S., Celik M., Vural A., Aydin B., Ozcelik M., GÖZÜ H.

ARCHIVES OF MEDICAL SCIENCE, vol.17, no.1, pp.1-8, 2021 (SCI-Expanded, Scopus)

• Publication Type: Article / Article
• Volume: 17 Issue: 1
• Publication Date: 2021
• Doi Number: 10.5114/aoms.2020.93264
• Journal Name: ARCHIVES OF MEDICAL SCIENCE
• Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus, Academic Search Premier, CAB Abstracts, CINAHL, EMBASE, Veterinary Science Database, Directory of Open Access Journals
• Page Numbers: pp.1-8
• Keywords: Intensive, degludec, co-formulation, premixed, DEGLUDEC/INSULIN ASPART, GLUCOSE VARIABILITY, PHASE 3A, HYPOGLYCEMIA, TARGET, BASAL, MANAGEMENT, GLARGINE, PEOPLE, ADULTS
• Marmara University Affiliated: Yes

Abstract

Introduction: To evaluate the efficacy and safety of transition from premixed and intensive insulin to twice-daily insulin degludec/aspart (IDegAsp) co-formulation in patients with type 2 diabetes mellitus.